A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor

• Published in: Diabetes, obesity & metabolism Vol. 26; no. 2; pp. 592 - 601
• Main Authors: Cui, Cheng, Cao, Fangrui, Kong, Iok Ian, Wu, Qinghe, Li, Fangqiong, Li, Haiyan, Liu, Dongyang
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.02.2024; Wiley Subscription Services, Inc
• Subjects: antidiabetic drug; Antidiabetics; Clinical trials; Decision making; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dosage; Dose-Response Relationship, Drug; DPP‐4 inhibitor; Drug development; Glycated Hemoglobin; Humans; Hypoglycemic Agents - pharmacology; Patients; Pharmacodynamics; Pharmacokinetics; type 2 diabetes; antidiabetic drug; drug development; pharmacokinetics; type 2 diabetes; DPP-4 inhibitor; pharmacodynamics

Aim To employ a model‐informed drug development approach in facilitating decision making and expediting the clinical progress of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 (DPP‐4) inhibitor, for the treatment of type 2 diabetes (T2D) via a biweekly dosing regimen. Method...